for Thanks, us Carrie, this thank you joining and everyone afternoon.
growing XXXX our made Let support ongoing me on start by base. strides work for and for to in their the thanking we our team focus hard huge commitment customer
and and will call to David drive provide the on review core areas share year, in more I’ll our for results to I revenue XXXX and our financial our will accomplishments and with begin XXXX. past over beyond. performance turn over today our of to call I outlook a focus details the Then growth then
bringing Seer of commercial than during to made a pushed first doubled the release for unbiased to unbiased instrument Excellence Proteograph Proteograph by year Product is to what established possible scale shipped number instruments across proteomic shipped accelerate as to we of North enabling adoption boundaries at was our providers compared broad December XX large Asia. to XXXX, access our We XXXX. of scale Product important Suite more provide of as year our strides We the and access Centers deep of program Suite. the XX, We of foundational deep cumulative the This Europe, to proteomics. XX at America, through and instruments the
claims. capitalized remain balance I’m and continued with property year million debt ended approximately representing will to proteomics, we our X,XXX with XXXX our to in And revenue years. operate while XXXX $XX.X more more the million our well revenue of the growth become pending, intellectual and portfolio and This on the patents XXX rate fuel of balance confident approximately our $X.X with and sheet outstanding. XXX%. doubling broaden of culminated over no issued the We than $XXX tools growth our efficient importantly, organization than a we coming in million definitive sheet in lean leader
bullish Product technology expanding will new applications Suite; our our catalyzing been markets; the execute three, across to four of breakthrough opportunities areas. differentiated of with the four, focus continue enabling core industry-leading discoveries XXXX, power today. to most change the technology; team. One, trajectory I Proteograph demonstrating our have we and two, and never has In about Seer more the proteomics. am I than our
with breakthrough Starting with Product objective science Proteograph enabling Suite. on our first the
of of a two impossible an ramping more was ranging our see coverage their ago. just unprecedented samples achieving hundreds scale use with at increasing of We’re established our an depth excited technology from studies interest thousands years in customers to larger to and that
what liquid be to improve they biopsy January, study biomarkers power cancer in of the molecular deep non-cancer fact, to diverse specificity XXX detection date. the results largest multi-omic subjects and X,XXX and comprised cancers the XXX study from our of believe of This PrognomiQ to demonstrated early sensitivity In one in across customers, of multi-omic early samples. announced the
the multi-omics half the subject clinical a XX,XXX in deep proteomics study data that success using and has unbiased Suite its in identifying metabolomics, the data controls a Product The first study. of between drive enrolled already transcriptomics methylation Proteograph with and upcoming markers fragmentomics, combined to first present which of perspective It generating this program, their catalyzed the at first of large-scale multi-omic kind to launch conferences expecting cancer differentiate lipidomics, its They’re patient. year. of
Prior largest the samples. of proteomic to XX plasma unbiased was Suite, launch the deep the study Proteograph just Product
thousand major Now, plus this planned deep field we XX,XXX years step in using how series of become just been function of existing samples of Proteograph. shows This more have studies unbiased implications studies. thousand We the for come on studies or we the of PrognomiQ’s product. representing what the of future deep run proteomics in has the short and far completed multi-omic of subject availability a subject have multiple study that know commercial change believe two has and possible progress
Another extralysosomal is in lysosomal disease disorders working Batten a of XX to disease lysosomal set genes, family a Rare drive novel of of proteins. Proteograph and Dr. of which Stanford the Research, the School rare of develop at of member Group is at Dr. Stanford mutations at a Brudvig example and therapeutic Disease South Batten of by of a Medicine, Pediatrics Jon from and biological Professor Brudvig, least better insights Pediatrics encode from caused one an of strategies. develop Dakota; and understanding the comes novel University Assistant diverse
of progress, effective signs symptoms including in seizure, There that and gene variety decades progressive the are dementia. Despite disorders research, remained range development a and has blindness, severity of loss, of vision therapies to leading intractable. and mutations, moving
a models. on the through immunodepletion proteomics simply interrogation processing like models, creating for fully Batten, discovery. Unfortunately, animal substantial not disease the is for phenotypes barrier recapitulate large slow into some required feasible For CLNX, animal biomarker small plasma samples, patient focus
X,XXX Brudvig, discovery team workflow Seer initiative. biomarker and a for Dr. to allowed Proteograph data generate his his working that shared multi-omic quantitative of unbiased Excellence Center Of Seer’s has transformative with Seer over been plasma new has team to the these Dr. biomarkers to and field. will signatures fill Batten in publish disease. find his which knowledge XXXX, in studies proteins plan disease on Brudvig the and important gaps
which We to than more is at the Proteograph believe deep the vastly and proteomic complex Suite genome. is catalog sufficiently the unbiased enabled Product that scale necessary proteome, by access
for characterized proteomics biomarkers. novel clinical clinical fuel insights is genomics functionally As generated. this These relative will applications content both be and to genome, will create cataloged new utility insights and novel the and
the and essential exemplification that multi-omic studies. We the the driven public insights are developing it differentiated market. become more proposition in Proteograph enters third-party data will Customer data the value the next-generation believe and as of provides novel established, more accelerating of domain, the
a our from at our XXX poster performance including and a published XX unique presentations nanoparticles. the technology of and conferences coming three to stream with engineered of have proprietary from steady validation seen papers high of presentations, Seer There’s impressed demonstrating with date. accepted paper We and fourth customers also posters events, over growing scientific content a impact
multi-omic to phenotype. content proteogenomic unbiased increasing to they discover seeing that to to protein access get the the can variants interest genomics are proteome insights closer access from We’re about novel excited deepen so and want who researchers their having and
advantage review in process takes In for course author submissions they multiple being move be of manuscripts. to early in submitted to take will which of process, share peer manuscripts with excited time. collaborate interim, been them analysis aware the share that their continue opportunities peer to from able review. We’re to the of conferences preliminary events data of months to through for submitted the our to study and or the customers run these in we have coming and I’m XXXX more as as
objective. attention to turning second Now, our our
superior Product Proteograph We’re papers is for unbiased of next of demonstrating performance the towards and unbiased extend seminal the XXXX, proteome for to engineered drive two In power of to nanoparticles. interactions demonstrated the we innovations technology our access the of we set power published Suite by demonstrating scalable our capabilities the as deep of nano-bio These the proprietary deep that further papers proteomics. enabled technology. the precise,
recognized by from the Award year, Suite XX the Proteograph also Top for Organization. the was among and Product disruptive Proteome The across Last Scientist, XXXX and being Technology our Science industry. Our Human we Innovation ranked technologies the received
We roadmap analysis. that are workflow product product building a executing against our on is disruptive nanoparticles what includes in already and innovations
workflow Last PAS way a that allows Proteograph Analysis X.X, to of genomic data proteogenomic for unbiased paves scale. the deep genomic variants proteomics streamlined protein released leverage labs to at and for variants analysis August, more we the Suite,
and peptide assess ability their genomic continue scale positive plan our data to from connect roadmap We have level population We and proteomic on been extremely data for later feedback disease expand receiving studies. software to to to easily association. deep proteomic customers
feature multiple for tools, our workflow will We into sets, data and Suite in Proteograph releases introduce XXXX. Analysis sets larger and study
in place product customers We and this our also the later late to expect hands broadly make it access we in of next XXXX, year. early available
variants. testing and subject potentially with of more Biobank is of X million study feedback X are which a new protein highly published features. cohort. over underscored This their Nature, proteome million positive sites multiple the complex The UK across potential completed protein on have with We getting millions workflow in XXX,XXX its describing are deleterious and is by by variants than
had participant an average X,XXX X,XXX of what protein each basis, which of individual an potentially On variants deleterious.
this generated that splice of to or because produce post-translational forms. protein account modifications are not Importantly, protein does processing variants for RNA
increases is technology our If why this then you the variants, exactly add protein it in, is significantly number these and important. of
the generating the using in paper accepted locus. identification Suite for we importance same at allow peptide highlight a the to In of from Product Proteograph the of gene for splice the level press and currently arising publications, form data
BMPX the The lung in short Our cancer BMPX of in isoform of be lung study currently is abundant and controls. review approaches and of more that on the exhibit are is in cases abundance while weeks forms. splice more based bio-archive. cannot published the controls. will three form that over form peer the between four note splice cases cancer is splice found This differential to BMPX known important coming of differentiate It inherently single available preprint affinity abundant manuscript
objective, catalyzing new to markets. third and Turning applications our
SCIEX, animal health, Consortium to with drive add Proteogenomic to we the and analysis progress expand partnerships clinical Discovery as that Life and researchers unprecedented the our the fluids. beginning skilled different model At resolution. translational discovery with such large genomics proteomic the to an our unbiased organisms, and at performed XXXX, Sciences can partners of form be bio with applications the and at Proteograph continuing deep We’re empowering studies
support running to customers and co-promote proteomic samples. launched for a biobank continuing creating and population access now development. area, multiple has in and and Sciences and with Boston the multi-omic in them ready specs Proteograph biomarker receive with the services to Life analysis studies are leading facility to expand the as forward to world-class partner Proteograph new mass scale to and look new to drug division Discovery provider customer scaled XXXX. they a large diagnostic up They’re their business We with characterization
biased in in the of and low-plex in used utility Product enabled a by a the Market a is we scale cannot measurement and here specific a development Their nucleotide a genomics are mutation to epitope cover we’re known a proteomic targeted single unbiased to value discovery approaches specific applications, deep at is complex part the our but differentiated or presence proteome. a desired Proteograph fragment microarrays demonstrate Affinity-based analogous utilized focus DNA clinical spanning of polymorphism. to Suite. specific or from for confirm is the of effective best as when specific target key manner to configuration vast
end approaches unbiased space the years. remains markets the end proteomics. to expansion complexity saw at depth out growing the similar XX in entirely a by gap The new We well reaches play enabled the as create genomic This in genomics content the scale. uniquely expand and huge that over with and past existing is market market content content of the will the access and end markets
key with with lab application Scientific used opinion that methods We’ve our an development in-house and and types Advisory sample on expanding expanding the we’re our be purely also opened efforts, focused leaders Through traction Proteograph. the market is that gaining Board. can
to low lower one this that than in XXX example, higher sample starting still less smaller projects assess of the volumes found enable sample XXXX to first work. For organism inputs of for allows coverage microliter We was volume lab entire we compared and volumes direct importantly, coverage microliter of digest low the across workflows. as while still proteins range. volume, standard starting as of XX coverage to We with our the get dynamic this delivering sample the explored XX% protein abundant
Proteograph This a superior such as The of decentralized canine, a looking only to few. size commercially those in has a be and been name that feline, smaller provides plants performance system wide model utilized bovine, available including to in a the mouse. manner. on is Proteograph variety organisms, demonstrated study baboon across method also to can organisms species The
As fluids recently Suite webinar we webinar how we the using call, hosted to mentioned This bio on a able was our data highlighted to Proteograph last discuss with thousands previously of earning Evotec human with proteins. technology. Product different their our uncover undetectable joint
The different well the and During home. webinar available This urine, plasma, presentation, sample is how Proteograph website. into the interest. types including serum, Evotec secret cerebrospinal recording unique human significant our highlighted fluid, was on and enabled insight generated cell attended
and agnostic species serum. plasma able Our technology analyze beyond and It is is is biofluids to inherently extensible.
cases in the As customer Proteograph even momentum our markets. commercial, and to we pave and more way growing translational, for use adoption pharma, of gain base our CROs technology spend academic the applied research, the for expand market, is the
for Interestingly, disease early we protein are to across target seeing these proteogenomics, variants multi-omics to and identification complex from discovery cataloging from broad from detection. a to of biomarker range disease customers applications working
at what very and onset much journey this customers next. I’m see to do We of the are excited our
we commercial as our our and global talent year with team year last than ended to finally, most we organization. more XXX top the continue an with to the employees recruit expand capabilities industry-leading support growing in We to base. additions install the And build
to continue core the discoveries its our demonstrating power, will Product with catalyzing areas, against markets, build ahead, and an industry-leading new focus execution Suite we applications breakthrough to drive enabling Looking continuing Proteograph and team.
labs the inspired I front of much omics in the the believe team, the and in phase the to While we bring that work by us. next to excited and globally. strategy the we’re technology, remains, opportunity have truly
With call now to will that, the I turn David. over
